SLC5A2 and hydrops fetalis: Among 12,251 patients with HF with mildly reduced or preserved LVEF in the DELIVER and EMPEROR-Preserved trials, SGLT2 inhibitors lowered the composite endpoint of CV or first hospitalization for HF (HR 0.80) with consistent decreases in both components of CV death (HR 0.88) and first hospitalization for HF (HR 0.74) [76].